PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

The consequences of neoadjuvant chemotherapy (NAC) for PD-L1 activity in triple-negative breast cancers (TNBC) are not well-understood. This is an important issue as PD-LI might act as a biomarker for immune checkpoint inhibitors’ (ICI) efficacy, at a time where ICI are undergoing rapid development...

Full description

Bibliographic Details
Main Authors: Beatriz Grandal, Manon Mangiardi-Veltin, Enora Laas, Marick Laé, Didier Meseure, Guillaume Bataillon, Elsy El-Alam, Lauren Darrigues, Elise Dumas, Eric Daoud, Anne Vincent-Salomon, Laure-Sophie Talagrand, Jean-Yves Pierga, Fabien Reyal, Anne-Sophie Hamy
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
breast cancer
neoadjuvant chemotherapy
PD-L1
immunohistochemistry
residual cancer burden
residual disease
Online Access:https://www.mdpi.com/2072-6694/13/4/746

Internet

https://www.mdpi.com/2072-6694/13/4/746

Similar Items